RegeneRx Biopharmaceuticals (RGRX)
Interview with: J.J. Finkelstein, President and CEO
Business News, Financial News, Stocks, Money & Investment Ideas, CEO Interview
and Information on their proprietary product, Thymosin
ßeta 4 (Tß4), for the healing of chronic wounds caused by disease, abrasion, or other
pathology. |
Cover Story
CEOCFO
Interview Index
CEOCFO Current
Issue
Future Features
Analyst Interviews
Corporate
Financials
Archived Interviews
About CEOCFOinterviews.com
Contact
& Ordering |
RegeneRx Biopharmaceuticals is
developing Thymosin Beta 4 (Tß4), a ground-breaking drug treatment for chronic wounds
Healthcare
Biotechnology & Drugs
(OTCBB: RGRX)
RegeneRx Biopharmaceuticals
J.J. Finkelstein
President and
Chief Executive Officer
Interview conducted by:
Lynn Fosse
Senior Editor
CEOCFOinterviews.com
July, 2003
Instant Access:
To find out more about:
RegeneRx
Biopharmaceuticals (RGRX)
you may order the complete text of our
interview. To view a copy of this highly informative interview, left click here: ViewRGRX
disclaimer
|
